Inhibiting EGFR and HER-2 simultaneously using a liposomal formulation of lapatinib resulted in enhanced amino-levulinic acid-PDT efficacies and prolonged survival in an orthotopic rat model of glioma [44]. Here, ERBB2 is linked to glioma.